FDA Grants Priority Review for Takeda (TAK) and Protagonist’s Rusfertide in PV Treatment

Takeda Pharmaceutical Company Limited (NYSE:TAK) is 1 of the most promising stocks nether $20. On March 2, Takeda and Protagonist Therapeutics announced that the US FDA accepted the New Drug Application and granted Priority Review for rusfertide. This investigational, first-in-class hepcidin mimetic is intended to dainty adults with polycythemia vera/PV, a uncommon humor crab characterized by the unsafe overproduction of reddish humor cells.

Given its imaginable to code important unmet needs, the FDA has acceptable a Prescription Drug User Fee Act enactment day for Q3 2026. The regulatory submission is supported by information from the Phase 3 VERIFY study, on with semipermanent results from the Phase 2 REVIVE and THRIVE trials. Clinical findings showed that rusfertide, erstwhile added to the modular of care, much than doubled effect rates compared to modular treatments alone. Key benefits included sustained power of hematocrit levels beneath 45%, a important simplification successful the request for achy phlebotomy procedures, and improvements successful patient-reported symptoms specified arsenic fatigue.

Under the 2024 collaboration agreement, Takeda is managing the regulatory strategy and aboriginal planetary filings, portion Protagonist maintains an enactment to co-commercialize the cause successful the US done a profit-sharing structure. Rusfertide works by mimicking the hormone hepcidin to modulate robust homeostasis, efficaciously targeting the underlying mechanics of the disease. If approved, it would supply a caller subcutaneous attraction enactment for patients who presently conflict to negociate humor thickness and the associated hazard of life-threatening thrombotic events similar strokes oregon embolisms.

Copyright: bbtreesubmission / 123RF Stock Photo

Takeda Pharmaceutical Company Limited (NYSE:TAK) researches, develops, manufactures, markets, and out-licenses pharmaceutical products successful Japan and internationally. It offers pharma products for gastroenterology, uncommon diseases, plasma-derived therapies, immunology, oncology, and neuroscience.

While we admit the imaginable of TAK arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 33 Stocks That Should Double successful 3 Years.

Disclosure: None. Follow Insider Monkey connected Google News.